Understand the source comparison
Peptide Comparison for CIRS Treatment
Thymosin Alpha-1 Upregulates T-regulatory cells, modulates Th1/Th2 balance TGF-beta1, autoimmune signaling 0.75–2mg per injection Subcutaneous 2–3x weekly for 8–12 weeks Best first-line peptide for immune dysregulation; measurable TGF-beta1 reduction in 60–70%
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1
- Upregulates T-regulatory cells, modulates Th1/Th2 balance
- TGF-beta1, autoimmune signaling
- 0.75–2mg per injection
- Subcutaneous
- 2–3x weekly for 8–12 weeks
- Best first-line peptide for immune dysregulation; measurable TGF-beta1 reduction in 60–70% of patients
- BPC-157
- Promotes angiogenesis, stabilizes nitric oxide, accelerates mucosal healing
- Zonulin, gut permeability, VEGF
- 250–500mcg daily
- Subcutaneous or oral
- Once daily for 4–8 weeks
- Critical for patients with gut symptoms; oral dosing less studied but used clinically for localized GI repair
- KPV
- Inhibits NF-kappaB, mimics alpha-MSH anti-inflammatory effects
- MSH deficiency, TNF-alpha, IL-6
- 500mcg–1mg per dose
- Subcutaneous or intranasal
- 1–2x daily for 6–12 weeks
- Addresses MSH deficiency without receptor desensitization; intranasal route bypasses first-pass metabolism
- LL-37
- Antimicrobial peptide, modulates immune response to bacterial/fungal antigens
- MMP-9, bacterial translocation
- 1–2mg per injection
- 2–3x weekly for 6–8 weeks
- Studied in chronic infection contexts; less CIRS-specific evidence but used for co-infections (Lyme, Bartonella)